Form 4: Phio Pharmaceuticals VP, CFO Robert Infarinato Reports Acquisition and Disposal of Common Stock

Robert M. Infarinato, VP and CFO of Phio Pharmaceuticals Corp., reports acquiring 3,000 shares of common stock and disposing of 11,000 shares.

Summary

• On September 11, 2024, Robert M. Infarinato, VP and CFO of Phio Pharmaceuticals Corp., reported transactions involving the company's common stock.
• He acquired 3,000 shares of common stock at a price of $0.
• He also disposed of 11,000 shares.
• Following these transactions, Infarinato beneficially owns shares of common stock, including shares underlying unvested restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the acquisition of shares is a positive sign, the disposal of a larger number of shares offsets this. The lack of context for the disposal makes it difficult to assess the overall impact.

Positives

• The acquisition of 3,000 shares indicates confidence in the company's future.

Negatives

• The disposal of 11,000 shares could be interpreted negatively by investors.

Risks

• The document does not provide specific reasons for the disposal of shares, which could lead to speculation and uncertainty.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.

Key Dates

Keywords

Form 4, Beneficial Ownership, Robert M. Infarinato, Phio Pharmaceuticals, PHIO, Common Stock, Restricted Stock Units, Acquisition, Disposal, CFO